PharmAla To Supply Amsterdam UMC with LaNeo(TM) MDMA, Including Development of New Single-Capsule Stability Data
MWN-AI** Summary
PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) has announced a significant binding supply agreement with Amsterdam University Medical Center (Amsterdam UMC) for the provision of its LaNeo™ MDMA capsules, specifically in a new 40mg single-capsule format. This partnership is intended to support a proposed clinical trial and marks a strategic expansion of PharmAla’s operations in Europe.
A key component of this agreement is the inclusion of a comprehensive three-year stability testing program for the newly packaged single-capsule dosage, which aims to generate essential stability data. This data will facilitate the future development of commercial-grade blister packaging for LaNeo™ MDMA, which is vital for pharmaceutical distribution. Nicholas Kadysh, CEO of PharmAla, expressed enthusiasm about the collaboration with Amsterdam UMC, highlighting its importance in enhancing their European clinical footprint and enabling the development of a commercially viable product.
The stability data acquired through this testing program is expected to enhance PharmAla's commercial strategy and enable more efficient distribution channels for clinical trial sites and commercial partners globally. PharmAla is uniquely positioned as a provider of clinical-grade MDMA for patient treatments beyond clinical trials, signifying its role as a pioneer in the sector.
Subject to the execution of a Quality Agreement with Amsterdam UMC and customary regulatory approvals, PharmAla is set to streamline access to LaNeo™ MDMA for researchers interested in conducting clinical trials. For further details on clinical access, researchers can visit PharmAla's dedicated page.
This agreement further solidifies PharmAla’s commitment to innovating within the biotechnology space, focusing on improving accessibility to critical therapeutic substances while adhering to stringent regulatory practices.
MWN-AI** Analysis
PharmAla Biotech Holdings Inc. is making notable strides in the MDMA research market with its recent supply agreement with Amsterdam UMC. This collaboration not only enhances PharmAla's European presence but also demonstrates their commitment to advancing clinical-grade MDMA's commercialization. As the company gears up to produce LaNeo™ MDMA capsules, the incorporation of a new single-capsule packaging format and a dedicated three-year stability testing program signals significant growth potential.
The stability data generated from this initiative will be pivotal, enabling PharmAla to transition to blister packaging that aligns with industry standards and optimizes distribution channels. Given the burgeoning interest in psychedelic therapy globally, PharmAla stands to benefit from a growing market, particularly with an established European value chain to support clinical research.
Investors should closely monitor PharmAla's progress with Amsterdam UMC and the subsequent stability data outcomes. These developments could catalyze an upward momentum in PharmAla’s stock performance, driven by the anticipated successful integration of blister packaging into their product line. Moreover, the company's emphasis on strong regulatory relationships positions it favorably in a sector that remains under scrutiny.
PharmAla's management's focus on research and development, particularly with their lead candidate, ALA-002, alongside their unique role in provisioning clinical-grade MDMA, enhances their market positioning. The current landscape presents opportunities for PharmAla as it bridges academic research and commercial viability.
In summary, as PharmAla Biotech advances with its strategic clinical partnerships and product development, prudent investors might consider positioning themselves in anticipation of increased market penetration and potential financial gains. However, it's imperative to remain cognizant of the inherent risks associated with developmental biotech ventures and the evolving regulatory environment surrounding psychedelics.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
TORONTO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), announced that it has executed a binding supply agreement with Amsterdam University Medical Center (“Amsterdam UMC”) in the Netherlands for the provision of LaNeo™ 40mg MDMA capsules for use in a proposed clinical trial.
Under the terms of the agreement, PharmAla will supply its LaNeo™ 40mg capsule dosage, repackaged in a new single-capsule packaging format. Critically, the agreement also includes a three-year stability testing program for the single-capsule dosage form, which will generate new stability data that PharmAla expects to leverage in the development of commercial-grade blister packaging for its LaNeo™ MDMA product line.
The stability data generated under this agreement is expected to provide critical support for PharmAla’s broader commercial strategy. Single-capsule stability data is a prerequisite for the development of blister packaging, which represents the commercial standard for pharmaceutical distribution. PharmAla anticipates that the data collected through this program may be bridged into the generation of new commercial-grade blister packaging for its LaNeo™ MDMA product, potentially enabling more efficient distribution to clinical trial sites and commercial partners globally.
“We are delighted to be working with Amsterdam UMC, one of Europe’s leading academic medical centres,” said Nicholas Kadysh, CEO of PharmAla Biotech. “This agreement is significant not only because it expands our European clinical footprint, but because the stability testing program included in the contract will generate single-capsule stability data that we intend to use as the foundation for developing blister packaging for LaNeo™ MDMA. This is an important step towards a truly commercial-grade product.”
PharmAla has an established European value chain and is positioned to support researchers across the continent with its LaNeo™ MDMA clinical research materials. The agreement with Amsterdam UMC is contingent upon the execution of a Quality Agreement with the Clinical Pharmacy of Amsterdam UMC. Delivery will be subject to customary regulatory approvals and the direction of the Amsterdam UMC team.
Researchers interested in accessing LaNeo™ MDMA for clinical trials may visit https://pharmala.ca/clinical-trials for additional information, including access to drug product quality documentation.
About PharmAla
PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials as well as commercial sales in selected jurisdictions, and to develop novel drugs in the same class. PharmAla is the only company currently provisioning clinical-grade MDMA for patient treatments outside of clinical trials. PharmAla’s research and development unit has completed proof-of-concept research into several IP families, including ALA-002, its lead drug candidate. PharmAla is a “regulatory first” organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators.
For more information, please contact:
Nicholas Kadysh
Chief Executive Officer
PharmAla Biotech Holdings Inc.
Email: press@PharmAla.ca
Phone: 1-855-444-6362
Website: www.PharmAla.ca
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement
This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on PharmAla’s current belief or assumptions as to the outcome and timing of such future events. Forward-looking information is based on reasonable assumptions that have been made by PharmAla at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. The forward-looking information contained in this press release is made as of the date hereof, and PharmAla is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in PharmAla’s management’s discussion and analysis which is available on PharmAla’s profile at www.sedar.com.
This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.
FAQ**
How does PharmAla's collaboration with Amsterdam UMC for LaNeo™ MDMA capsules impact its stock performance, particularly under the ticker MDXXF?
What specific advantages does the stability testing program provide PharmAla Biotech in enhancing its market position for MDXXF products?
What are the potential implications of the binding supply agreement for PharmAla's growth strategy regarding clinical-grade MDMA stock MDXXF?
How might the development of commercial-grade blister packaging for LaNeo™ MDMA influence investor sentiment and stock performance for MDXXF?
**MWN-AI FAQ is based on asking OpenAI questions about Pharmala Biotech Holdings Inc. (CNQC: MDMA:CC).
NASDAQ: MDMA:CC
MDMA:CC Trading
0.0% G/L:
$0.03 Last:
163,753 Volume:
$0.03 Open:
